Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | IDRA | Series X Preferred Stock | Other | +5 | 5 | Sep 28, 2022 | NovaQuest Co-Investment Fund XV, L.P. | F1, F2 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | IDRA | Warrants | Other | +1.34M | 1.34M | Sep 28, 2022 | Common Stock | 1.34M | $0.46 | NovaQuest Co-Investment Fund XV, L.P. | F2, F3 | |||
transaction | IDRA | Warrants | Other | +14.1K | 14.1K | Sep 28, 2022 | Series Z Preferred Stock | 14.1K | $460.00 | NovaQuest Co-Investment Fund XV, L.P. | F2, F3 | |||
transaction | IDRA | Series Z Preferred Stock | Other | +14.1K | 14.1K | Sep 28, 2022 | Common Stock | 14.1M | NovaQuest Co-Investment Fund XV, L.P. | F2, F3, F4, F5 |
Id | Content |
---|---|
F1 | On September 28, 2022, Idera Pharmaceuticals, Inc. ("Idera") completed its merger ("Merger") with Aceragen, Inc. ("Aceragen"), in accordance with the terms of that certain Agreement and Plan of Merger, dated September 28, 2022 (the "Merger Agreement"). In connection with the Merger, NovaQuest Co-Investment Fund XV, L.P. ("NovaQuest") received five shares of the Issuer's non-voting, non-convertible Series X Preferred Stock in exchange for five shares of Aceragen Series X Preferred Stock. |
F2 | NQ POF V GP, Ltd. ("NovaQuest GP") has the power to vote and dispose of any securities directly owned by NovaQuest. NovaQuest GP's investment committee makes voting and investment decisions regarding securities held by NovaQuest. The Reporting Person is a member of the investment committee NovaQuest GP. The Reporting Person disclaims beneficial ownership of any securities held by NovaQuest except to the extent of its pecuniary interest therein. |
F3 | Pursuant to the Merger Agreement, NovaQuest received Idera warrants for 1,343,547 shares of common stock of Idera, par value $0.001 ("Common Stock") and warrants for 14,115 shares of Series Z Non-Voting Convertible Preferred Stock, par value $0.01 ("Series Z Preferred Stock"), in exchange for a warrant to purchase 618,800 shares of Aceragen common stock. |
F4 | Represents Series Z Preferred Stock issuable upon the exercise of the Series Z Preferred Stock warrants reported above. |
F5 | Contingent upon stockholder approval of the conversion of Series Z Preferred Stock into shares of Common Stock, each share of Series Z Preferred Stock is convertible 1,000 shares of Common Stock, at any time at the option of the holder thereof, subject to certain limitations. |